Diuretic Therapy in Fluid-Overloaded and Heart Failure Patients

2010 ◽  
pp. 153-163 ◽  
Author(s):  
Rinaldo Bellomo ◽  
John R. Prowle ◽  
Jorge E. Echeverri
Keyword(s):  
Heart Failure ◽  
Diuretic Therapy ◽  
Heart Failure Patients

Diuretic response and effects of diuretic omission in ambulatory heart failure patients on chronic low‐dose loop diuretic therapy

2021 ◽  
Author(s):  
Jeroen Dauw ◽  
Pieter Martens ◽  
Gregorio Tersalvi ◽  
Joren Schouteden ◽  
Sébastien Deferm ◽  
...  
Keyword(s):  
Heart Failure ◽  
Low Dose ◽  
Loop Diuretic ◽  
Diuretic Therapy ◽  
Heart Failure Patients ◽  
Diuretic Response

scholarly journals Prevalence of thiamine deficiency in heart failure patients on long-term diuretic therapy

2015 ◽  
Vol 1 (1) ◽  
pp. 25 ◽  
Author(s):  
Shrenik Doshi ◽  
T Velpandian ◽  
Sandeep Seth ◽  
SK Maulik ◽  
Balram Bhargava ◽  
...  
Keyword(s):  
Heart Failure ◽  
Thiamine Deficiency ◽  
Diuretic Therapy ◽  
Heart Failure Patients

Ultrafiltrazione peritoneale e sindrome cardiorenale: gestione del sovraccarico di fluidi e ruolo del sodio

2019 ◽  
Vol 31 (2) ◽  
pp. 100-105
Author(s):  
Luca Di Lullo ◽  
Claudio Ronco ◽  
Fulvio Floccari ◽  
Antonio De Pascalis ◽  
Rodolfo Rivera ◽  
...  
Keyword(s):  
Heart Failure ◽  
Peritoneal Dialysis ◽  
Diuretic Therapy ◽  
Decompensated Heart Failure ◽  
Cardiorenal Syndrome ◽  
Therapeutic Modality ◽  
Heart Failure Patients ◽  
Sodium Removal ◽  
Refractory Heart Failure ◽  
Home Based

Congestion represents a crucial clinical component of both heart failure and cardiorenal syndrome and it has been postulated to modulate heart and kidney cross-link. Diuretic therapy is a corner stone in the treatment patients with heart failure, and renal replacement therapies are mainly used for patients with refractory heart failure who have not reached the worst stages of renal disfunction. Peritoneal dialysis is a home-based therapeutic modality providing both solute clearance and ultrafiltration, together with relief from congestion in decompensated heart failure patients. The following review will focus on sodium removal in refractory decompensated heart failure patients undergoing peritoneal dialysis. (Cardionephrology)

scholarly journals OUTCOMES OF ULTRAFILTRATION IN ADVANCED HEART FAILURE PATIENTS RESISTANT TO DIURETIC THERAPY

2014 ◽  
Vol 30 (10) ◽  
pp. S199
Author(s):  
M. Moussa ◽  
S. Zuberi ◽  
T. Friesen ◽  
F. Cordova ◽  
S. Zeiroth
Keyword(s):  
Heart Failure ◽  
Diuretic Therapy ◽  
Advanced Heart Failure ◽  
Heart Failure Patients

scholarly journals Cost Analysis of Combination Diuretic Therapy with Ace-Inhibitors to Diuretic Therapy without Ace-Inhibitors in Heart Failure Patients

2016 ◽  
Vol 15 (3) ◽  
pp. 368-375
Author(s):  
Fajar Wahyu Pribadi ◽  
Iwan Dwiprahasto ◽  
Jarir At Thobari
Keyword(s):  
Heart Failure ◽  
Combination Therapy ◽  
Cost Analysis ◽  
Ace Inhibitors ◽  
Ace Inhibitor ◽  
Diuretic Therapy ◽  
Medical Science ◽  
High Morbidity ◽  
Major Health Problem ◽  
Heart Failure Patients

Background: Heart failure is the final stage of the entire heart disease and become a major health problem because of the high morbidity and mortality. Diuretic combination therapy with ACE inhibitors compared to diuretic therapy without ACE inhibitors will affect the costs and hospitalization for heart failure patients; so it can be used to study Pharmacoeconomics.Method and Design: This study is an analytic observational retrospective cohort study design. Researchers compared the cost analysis between groups having diuretic combination therapy with an ACE inhibitor and diuretic therapy without ACE inhibitors. Data taken with a total sampling of heart failure databases claimed prescribing health insurance PT. ASKES Persero between January 1, 2010 until December 31, 2011.Results: Out of the 377 patients of the study population, 64 patients received combination therapy with ACE inhibitors and diuretics, and 60 patients received diuretic therapy without ACE inhibitors. The analysis showed that the total cost was Rp. 4.96 million and Rp. 5.14 million; the average total inpatient days a year was 10.67 days and 7.00 days.Conclusion: This study showed that the diuretic combination therapy with an ACE inhibitor is more cost-effective. Further research is needed to assess the total costs and effectiveness of therapy with more number of subjects and longer periods.Bangladesh Journal of Medical Science Vol.15(3) 2016 p.368-375

scholarly journals Ultrafiltration is better than diuretic therapy for volume-overloaded acute heart failure patients: a meta-analysis

2020 ◽  
Author(s):  
Bastian Wobbe ◽  
Juliane Wagner ◽  
Dorottya Kata Szabó ◽  
Ildikó Rostás ◽  
Nelli Farkas ◽  
...  
Keyword(s):  
Heart Failure ◽  
Weight Loss ◽  
Acute Decompensated Heart Failure ◽  
Meta Analysis ◽  
Diuretic Therapy ◽  
Systematic Evaluation ◽  
Effective Treatment Option ◽  
Fluid Removal ◽  
Heart Failure Patients ◽  
The Impact

AbstractStudies on the effectiveness of ultrafiltration (UF) in patients hospitalized with acute decompensated heart failure (ADHF) have led to heterogeneous study outcomes. This meta-analysis aimed to assess the impact of UF therapy in ADHF patients. We searched the medical literature to identify well-designed studies comparing UF with the usual diuretic therapy in this setting. Systematic evaluation of 8 randomized controlled trials enrolling 801 participants showed greater fluid removal (difference in means 1372.5 mL, 95% CI 849.6 to 1895.4 mL; p < 0.001), weight loss (difference in means 1.592 kg, 95% CI 1.039 to 2.144 kg; p < 0.001) and lower incidences of worsening heart failure (OR 0.63, 95% CI 0.43 to 0.94, p = 0.022) and rehospitalization for heart failure (OR 0.54, 95% CI 0.36 to 0.82, p = 0.003) without a difference in renal impairment (OR 1.386, 95% CI 0.870 to 2.209; p = 0.169) or all-cause mortality (OR 1.13, 95% CI 0.75 to 1.71, p = 0.546). UF increases fluid removal and weight loss and reduces rehospitalization and the risk of worsening heart failure in congestive patients, suggesting ultrafiltration as a safe and effective treatment option for volume-overloaded heart failure patients.

scholarly journals Influence of diuretic therapy on the features of heart rhythm variability changes in chronic heart failure patients

2018 ◽  
Vol 99 (1) ◽  
pp. 23-29
Author(s):  
K R Alyeva ◽  
A B Bakhshaliev ◽  
S M Kakhramanova
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Diuretic Therapy ◽  
Heart Rhythm ◽  
Heart Rhythm Variability ◽  
Heart Failure Patients

Цель. Изучить сравнительное влияние фуросемида и торасемида на показатели вариабельности ритма сердца у пациентов с хронической сердечной недостаточностью ишемического генеза. Методы. В исследование вошли 48 пациентов (29 мужчин и 19 женщин) с ишемической болезнью сердца, осложнённой хронической сердечной недостаточностью II-IV функциональных классов по NYHA. Все пациенты были рандомизированы на две группы: первая группа (25 человек) в качестве диуретической терапии получала фуросемид, вторая (23 человека) - торасемид. Всем больным проводили клиническое обследование, включающее оценку жалоб и данных объективного состояния, лабораторные и инструментальные исследования (электрокардиографию, эхокардиографию, тест 6-минутной ходьбы, 24-часовое мониторирование электрокардиограммы по Холтеру) до начала диуретической терапии и через 30 дней после неё. Результаты. На фоне проведённой 1-месячной диуретической терапии зарегистрирована позитивная динамика клинических параметров в обеих основных группах пациентов, получающих лечение как фуросемидом, так и торасемидом. На фоне лечения фуросемидом отмечено ухудшение параметров вариабельности ритма сердца. Терапия торасемидом привела к значительному улучшению показателей вегетативной регуляции сердечной деятельности. Вывод. Мочегонная терапия фуросемидом характеризуется изменениями временных и спектральных параметров вегетативной регуляции сердечного ритма в сторону усиления симпатических и ослабления парасимпатических влияний; диуретическая терапия торасемидом сопровождается значительным улучшением показателей вариабельности ритма сердца, ослаблением симпатических и усилением парасимпатических влияний на ритм сердца, что обеспечивает дополнительную кардиопротекцию при лечении пациентов с хронической сердечной недостаточностью ишемического генеза.

Sign in / Sign up

Export Citation Format

Share Document